ERBB2 and breast cancer: However, previous studies have indicated controversies regarding the efficacy of CDK4/6 inhibitors in combination with endocrine therapy for HR-positive/HER2-negative early breast cancer (Slamon et al., 2024; Gnant et al., 2022; Loibl et al., 2021).